f
or nearly two years, Dr. Pierre Kory has been trying to tell the United States and the world that Ivermectin is highly effective in preventing COVID-19. On January 5, following the release of “the 16th positive, statistically significant trial” reinforcing the effectiveness of the affordable drug, Kory reiterated that same message. Indeed, the latest study proving Ivermectin’s effectiveness was a gold-standard randomized clinical trial (RCT) conducted by MedinCell.
The study, conducted on 399 patients, met its primary efficacy endpoint with a reduction of 75 percent of COVID-19 infection in the group treated with daily oral administration of Ivermectin compared to the placebo group. All participants were unvaccinated adults and had been exposed to the virus within five days of screening after documented close contact with a person who had a PCR-confirmed SARS-CoV-2 infection. After administering Ivermectin for 28 days, the drug showed acceptable safety and tolerability with zero unforeseen safety signals.
Hmm. The 16th positive, statistically significant, controlled trial that finds ivermectin is HIGHLY effective in PREVENTING Covid-19. Been trying to tell the U.S. & world about this for 2 years. Thanks @elonmusk
— Pierre Kory, MD MPA (@PierreKory) January 6, 2023
RCT: IVM Reduces 72% COVID-19 Infection https://t.co/pcYWvWyU8k pic.twitter.com/Ay9zgTHLTD
